A combined strategy of EGFR-MET bispecific antibody and HER3 ADC to overcome osimertinib resistance in NSCLC
Cellular Oncology · 2026
DOI: 10.1007/s13402-025-01152-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cellular Oncology, 2026. Verfasst von Yuanyuan Wang und 11 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Tongji University, Shanghai, 200092, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Drug Resistance, Neoplasm, Lung Neoplasms, Acrylamides. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Shanghai Innovative Collaboration Project.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Medicine, Tongji University, Shanghai, 200092, China.
- Department of Oncology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, 200092, China.
- Department of Medical Oncology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, 200092, China.
- Department of Oncology, The First Affiliated Hospital of Army Medical University, Chongqing, China.
- Graduate School of Bengbu Medical University, Bengbu, China.
- Department of Lung Cancer and Immunology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China.
Förderung
- Shanghai Innovative Collaboration Project
Zitieren
APA
Wang, Y., Guo, H., Han, R., Wu, Y., He, T., Diao, M., Xiong, A., Zhou, F., Cheng, L., Zhao, C., Li, X., & Zhou, C. (2026). A combined strategy of EGFR-MET bispecific antibody and HER3 ADC to overcome osimertinib resistance in NSCLC. Cellular Oncology. https://doi.org/10.1007/s13402-025-01152-8
Vancouver
Wang Y, Guo H, Han R, Wu Y, He T, Diao M, et al. A combined strategy of EGFR-MET bispecific antibody and HER3 ADC to overcome osimertinib resistance in NSCLC. Cellular Oncology. 2026. doi:10.1007/s13402-025-01152-8
BibTeX
@article{Wang2026,
author = {Wang, Yuanyuan and Guo, Haoyue and Han, Ruoshuang and Wu, Yuhan and He, Taiping and Diao, Meng and Xiong, Anwen and Zhou, Fei and Cheng, Lei and Zhao, Chao and Li, Xuefei and Zhou, Caicun},
title = {A combined strategy of EGFR-MET bispecific antibody and HER3 ADC to overcome osimertinib resistance in NSCLC},
journal = {Cellular Oncology},
year = {2026},
doi = {10.1007/s13402-025-01152-8}
}
EUVIMED